Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

1 results
12:00 AM, Aug 05, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

AF802: Phase II started

disclosed in its 2Q13 earnings that it began a dose-escalation Phase II trial to evaluate RG7853
Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan   Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland   Product: AF802
CH5424802 , RG7853   Business: Cancer   Molecular target: Anaplastic lymphoma kinase (ALK)   Description …